Inventor · disambiguated record
Edward Ha
Also filed as: HA EDWARD · HA EDWARD H · HA EDWARD HYUNGSUK
14 granted patents·20 pending applications·175 citations·filing 2003–2024
91Inventor score
Files withANGIEX INC8TALLAC THERAPEUTICS INC6MAGENTA THERAPEUTICS INC4IGENICA BIOTHERAPEUTICS INC3GENENTECH INC2
Top patents by PatentIndex Score
34 records- 0195US7947839B2Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of useGENENTECH INC·Filed 2006·Granted May 24, 2011·53 cites·16 claims
- 0293US8742076B2Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methodsCOHEN ROBERT L·Filed 2009·Granted Jun 3, 2014·28 cites·8 claims
- 0392US9492553B2Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methodsGENENTECH INC·Filed 2014·Granted Nov 15, 2016·8 cites·4 claims
- 0490US7161002B2Syntheses of quinazolinonesSMITHKLINE BEECHAM CORP·Filed 2005·Granted Jan 9, 2007·36 cites·12 claims
- 0589US11795463B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·16 claims
- 0688US7009049B2Syntheses of quinazolinonesSMITHKLINE BEECHAM CORP·Filed 2003·Granted Mar 7, 2006·37 cites·11 claims
- 0785US11920136B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2021·Granted Mar 5, 2024·1 cites·47 claims
- 0885US11229711B2Linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Jan 25, 2022·3 cites·5 claims
- 0984US11203611B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useSOLSTICE BIOLOGICS LTD·Filed 2018·Granted Dec 21, 2021·5 cites·35 claims
- 1084US10781259B2Modified antibodies and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Sep 22, 2020·3 cites·29 claims
- 1179US2024191242A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1278US2024287528A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1367US2020392108A1Antibody-drug conjugates and related compounds, compositions and methodsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1466US12351598B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useTALLAC THERAPEUTICS INC·Filed 2021·Granted Jul 8, 2025·0 cites·44 claims
- 1566US2023109312A1Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1662US2014363454A1Antibody-Drug Conjugates, Compositions and Methods of UseIGENICA BIOTHERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1762US2013224228A1Antibody-Drug Conjugates and Related Compounds, Compositions, and MethodsIGENICA INC·Filed 2012·Application pending·0 cites
- 1859US11932695B2Modified antibodies and related compounds, compositions and methods of useSENSEI BIOTHERAPEUTICS INC·Filed 2020·Granted Mar 19, 2024·0 cites·6 claims
- 1959US2025152730A1Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using sameANGIEX INC·Filed 2024·Application pending·0 cites
- 2058US2024342302A1Degrader-antibody conjugates and methods of using sameANGIEX INC·Filed 2024·Application pending·0 cites
- 2158US2024156978A1Maytansine-antibody conjugates and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 2257US2023372518A1Antimitotic tetrapeptide-antibody conjugates and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 2355US2018147294A1Antibody-drug conjugates, compositions and methods of useJACKSON DAVID Y·Filed 2017·Application pending·0 cites
- 2454US2016303247A1Antibody-Drug Conjugates and Related Compounds, Compositions, and MethodsIGENICA BIOTHERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 2553US2023364255A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2652US2023293713A1Anti-tm4sf1 antibody drug conjugates and methods of using sameANGIEX INC·Filed 2022·Application pending·0 cites
- 2751US2015231240A1Anti-c16orf54 antibodies and methods of use thereofIGENICA INC·Filed 2013·Application pending·0 cites
- 2851US2023126271A1Degrader-antibody conjugates and methods of using sameANGLEX INC·Filed 2022·Application pending·0 cites
- 2950US2023338572A1Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 3048US2023116407A1Systems and Methods for Predicting Consumer Spending and for Recommending Financial ProductsSOON SCIENCE INC·Filed 2021·Application pending·0 cites
- 3146US2007134243A1Antibody drug conjugates and methodsGAZZARD LEWIS J·Filed 2005·Application pending·0 cites
- 3244US12458705B2Antibody-oligonucleotide conjugatesANGIEX INC·Filed 2019·Granted Nov 4, 2025·0 cites·12 claims
- 3342US12428477B2Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the sameANGIEX INC·Filed 2020·Granted Sep 30, 2025·0 cites·7 claims
- 3438US2019209704A1Novel antibody-drug conjugates and related compounds, compositions and methods of useIGENICA BIOTHERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Edward Ha files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →